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ABSTRACT. The programme for the 2015 AAPS Annual Meeting and Exhibition
(Orlando, FL; 25–29 October 2015) included a sunrise session presenting an overview of the
state-of-the-art tools for in vitro–in vivo extrapolation (IVIVE) and mechanistic prediction of
renal drug disposition. These concepts are based on approaches developed for prediction of
hepatic clearance, with consideration of scaling factors physiologically relevant to kidney and
the unique and complex structural organisation of this organ. Physiologically relevant kidney
models require a number of parameters for mechanistic description of processes, supported
by quantitative information on renal physiology (system parameters) and in vitro/in silico
drug-related data. This review expands upon the themes raised during the session and
highlights the importance of high quality in vitro drug data generated in appropriate
experimental setup and robust system-related information for successful IVIVE of renal drug
disposition. The different in vitro systems available for studying renal drug metabolism and
transport are summarised and recent developments involving state-of-the-art technologies
highlighted. Current gaps and uncertainties associated with system parameters related to
human kidney for the development of physiologically based pharmacokinetic (PBPK) model
and quantitative prediction of renal drug disposition, excretion, and/or metabolism are
identiﬁed.
KEYWORDS: active renal excretion; human kidney transporters; human renal drug clearance; kidney
disease; non-hepatic drug metabolism.
INTRODUCTION
The recent paradigm shift to systems pharmacology
approaches in drug development sets out an increased usage
of quantitative concepts for linking in vitro observations on
drug characteristics to their biological behaviour. Many
complex aspects of hepatic drug disposition have been
addressed over the last decade using systems pharmacology
approaches, with implications for population variability in
pharmacokinetics (1), as well as adverse events in liver such
as drug-induced liver injury (2). However, the same cannot be
claimed for predicting renal disposition under various condi-
tions or the covariates determining nephrotoxicity.
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The kidneys have a signiﬁcant role in the clearance of
many drugs. Within the top 200 drugs prescribed in the
USA in 2010, 32% of them had ≥25% of the absorbed
dose excreted unchanged in urine (3). The kidneys are
also involved in drug metabolism due to expression of a
number of drug-metabolising enzymes, as summarised in
Table I. Mechanistic kidney models that mathematically
describe underlying processes involved in renal drug
disposition can be complex in order to capture the
biological heterogeneity of this organ (4, 5).
Physiologically based pharmacokinetic (PBPK) models
recognise different types of model parameters representing
either properties of a drug, biological system and/or trial
design, each requiring information from different sources
(1, 6). System parameters are typically informed by
quantitative data on the organ physiology, whereas data
from in vitro experimental data can be used to inform
drug-speciﬁc parameters. In vitro–in vivo extrapolation
(IVIVE) is now a widely adopted approach for prediction
of pharmacokinetic parameters from in vitro data (‘bottom-
up’). IVIVE utilises scaling factors to account for differ-
ences between in vitro systems and in vivo situation (1).
For example, microsomal metabolism data, reported as
activity or intrinsic clearance (CLint) per milligram of
microsomal protein, are scaled by the amount of micro-
somal protein per gram of the organ of interest, e.g.
microsomal protein per gram kidney (MPPGK) in the case
of kidney (7). Expression of a speciﬁc protein is accounted
for by the relative expression factor (REF), which repre-
sents the ratio of the abundance of a particular protein
(e.g. organic anion transporter (OAT) 3 (OAT3,
SLC22A8)) in the kidney in vivo compared with the
expression in the cellular system used to generate the in
vitro data (5, 8). Similarly, the relative activity factor
(RAF) may be applied, which accounts for differences in
activity of a protein of interest between in vivo and in vitro
by using a selective probe substrate.
The overall aim of this two-part review is to analyse the
current status and gaps in the knowledge required for
quantitative prediction of renal drug disposition within the
PBPK paradigm. The goal of part I is to outline the various
sources of data required to inform parameters in IVIVE-
based mechanistic kidney models to predict renal drug
disposition. A critical overview of different in vitro tools
currently available to investigate renal drug metabolism and
transport is provided. The need for high quality in vitro drug
data generated using appropriate experimental systems is
emphasised. The second section of this paper critically
assesses the current knowledge (and existing gaps) of the
quantitative kidney anatomy and physiology data, of rele-
vance for IVIVE renal scaling factors and PBPK system
parameters. Part II of this review will focus on the
availability, application and suitability of mechanistic models
of renal drug excretion and/or metabolism, including the
dynamics of drug disposition in kidney cells and the need
for appropriate clinical data (Scotcher D, Jones C, Posada
M, Galetin A, Rostami-Hodjegan, A., in preparation).
It should be noted that extensive review and listing of the
multitude of enzymes and transporters whichmay be involved in
the metabolism and excretion of drugs by the kidney are outside
the scope of this review. For such information, readers are
referred to previous studies and reviews (9–12).
USE OF IN VITRO SYSTEMS TO UNDERSTAND
RENAL DRUG ELIMINATION
In vitro assays are routinely used during drug develop-
ment to optimise the ADME properties of compounds and
provide critical input to inform selection of appropriate
dosing strategies in clinical trials. This information may relate
to systemic or local tissue drug concentrations of relevance
for the assessment of drug–drug interaction (DDI) risk and/or
toxicity. Decision-making in drug development relies heavily
on in vitro experimental data and subsequent modelling
efforts. It is therefore essential that in vitro data are of high
quality and generated using appropriate assay formats
relevant for the scientiﬁc questions asked. It is also critical
that any limitations of speciﬁc assays (e.g. inter and intra-
laboratory variability) and impact of data analysis (e.g.
mechanistic modelling of in vitro data) on parameter values
are understood by scientists involved in the translational
implementation of such data using modelling and simulation.
In Vitro Systems for Studying Renal Drug Metabolism
Table I summarises the most relevant drug-metabolising
enzymes expressed in the human kidney, together with the in
vitro systems used and corresponding scaling factors necessary
for IVIVE of renal metabolic clearance. Despite their physio-
logical complexity, proximal tubule cells are not used on a
regular basis for renal metabolism studies, mainly due to limited
availability of high quality human kidney tissue. In addition,
expression of key drug-metabolising enzymes in proximal tubule
cells has been reported to reduce with time in culture (13). For
certain drugs, potential impact of renal drug transporters
expressed in proximal tubule cells also needs to be taken into
consideration. Analogous to hepatocytes, IVIVE of renal
metabolism in vitro data from isolated proximal tubule cells
could be performed using proximal tubule cell number per gram
kidney (PTCPGK) as a scaling factor.
It is evident from Table I that human kidney subcellular
fractions (microsomes, S9) and recombinant enzyme expres-
sion systems are the most commonly applied sources of
kidney drug-metabolising enzymes in in vitro assays (7, 14–
16). Subcellular fractions require supplementation with ap-
propriate cofactors lost during the preparation procedure and
these are highlighted in Table I. Kidney microsomes are the
most frequently used system to investigate either cytochrome
P450 (CYP) or glucuronidation (UGT)-mediated metabolism,
whilst 9000g supernatant (S9) or cytosolic preparations are
considered if glutathione-S-transferase (GST) or
carboxylesterase (CES)-mediated metabolism in the kidney
are of relevance. Analogous to human liver microsomes,
investigation of renal glucuronidation requires inclusion of
alamethicin. This pore-forming peptide disrupts microsomal
membranes to overcome reaction latency associated with
UGTs due to localisation of the enzyme active site facing the
lumen of the endoplasmic reticulum (7, 17). Furthermore, the
addition of albumin has been implemented in the renal
glucuronidation in vitro assays (7) in order to account for
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the inhibitory effect of fatty acids released during microsomal
incubations on UGTs. Although the ‘albumin’ effect is
enzyme speciﬁc, its inclusion in the in vitro assay improved
prediction accuracy of renal glucuronidation clearance when
using microsomal data (7). Identiﬁcation of the individual
enzymes contributing to the overall renal metabolic clearance
can be done through reaction phenotyping and use of
selective chemical inhibitors. A number of selective inhibitors
Table I. Summary of Key Drug-Metabolising Enzyme Isoforms in Human Kidney




Substrates Suitable in vitro system +
cofactor/scaling factora
CYP3A5 Cynomolgus monkey Liver and intestine Cortex and
medulla
Ifosfamide,
c yc l o spor i n A ,
tacrolimus
Human kidney microsomes +
NADPH/MPPGK
rhCYP/RAF





in PT and LoH
Dextromethorphan,
bufuralol









PT S - m e t h y l N ,N -
diethyldithiocarbom-
ate, sulphides
Human kidney microsomes +
NADPH/MPPGKb
rhFMO/RAF
ADH/ALDH Ubiquitous Liver ADH: PT





Human kidney cytosol +
NAD+ (ADH) or NADP+
(ALDH)/CPPGK
CES2 Rat, mouse Liver and intestine PT, Bowman ’ s
capsule
Irinotecan, prodrugs Human kidney S9/S9PPGK
AKR1A1 Mouse/rat isoforms
differ to human






UGT1A9 UGT1A family in
most preclinical
species




Human kidney microsomes +
UDPGA, a l ame th i c i n c /
MPPGK





Liver and intestine PT, LoH, DT, CD Efavirenz,
zidovudine
Human kidney microsomes +







Testis, brain LoH, DT Carmustine Human kidney cytosol +
GSH/CPPGK
Human kidney S9 + GSH/
S9PPGK







Ethac ryn i c a c i d ,
chlorambucil
Human kidney cytosol +
GSH/CPPGK






m e d u l l a ,
collecting ducts,
endothelium
Chlorambucil (rat) Human kidney microsomes +
GSH/MPPGK
Human kidney S9 + GSH/
S9PPGK
References are provided in the supplementary material
ADH alcohol dehydrogenase, AKR aldo/keto reductase, ALDH aldehyde dehydrogenase, CD collecting duct, CES carboxylesterase, CPPGK
cytosolic protein per gram kidney, CYP cytochrome P450, DT distal tubule, FMO ﬂavin containing monooxygenase, GSH glutathione, GST
glutathione-S-transferase, LoH loop of Henle, MGST microsomal glutathione-S-transferase, MPPGK microsomal protein per gram kidney,
NADPH nicotinamide adenine dinucleotide phosphate, PT proximal tubule, PTCPGK proximal tubule cells per gram kidney, RAF relative
activity factor, rhCYP/rhUGT human enzyme in recombinant expression system, S9PPGK S9 protein per gram kidney, S9 supernatant from
9000g differential centrifugation, UDPGA uridine diphosphate glucuronic acid, UGT uridine diphospho-glucuronosyltransferase
a Freshly isolated human proximal tubule cells (expression of drug-metabolising enzymes rapidly decreases during cell culture) can be used for
holistic drug metabolism assays, although enzymes expressed in other tubular regions (LoH, DT, CD) may not be represented—such data
should be scaled using PTCPGK
bDifferentiation from CYP-mediated metabolism challenging, although heat treatment (45°C for 2 min in absence of NADPH) is suggested to
speciﬁcally inactivate FMO, whereas 1-aminobenzotriazole and methimazole are non-speciﬁc inhibitors of CYP and FMO enzymes,
respectively
cAdditional cofactors including MgCl2, saccharic acid lactone and bovine serum albumin have been proposed, although apparent beneﬁts and
optimal conditions vary between studies and UGT enzymes
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have been reported for UGT1A9 (e.g. niﬂumic acid and
diﬂunisal) and UGT2B7 (e.g. ﬂuconazole); however, some of
these can also inhibit other UGTs, albeit at higher concen-
trations (17, 18). Consideration of the region of human
kidney subcellular fractions used in drug metabolism studies
is also of importance. Most studies use kidney cortex, but
expression and activity of UGT and GST enzymes have also
been demonstrated in the kidney medulla (Table I). In many
cases, pooled kidney microsomes from either unspeciﬁed
region or with no information on the proportion of the cortex
and medulla are used in the renal metabolism studies.
Analogous to hepatic CYPs and UGTs, evidence of atypical
enzyme kinetics (i.e. not following standard Michaelis-
Menten behaviour) has been reported in human kidney
microsomes (19). Such atypical kinetics requires appropriate
modelling of in vitro data and subsequent IVIVE. For
example, in the case of auto-activation, determination of
maximal intrinsic clearance (CLmax) is proposed as a substi-
tute for standard CLint in the scaling process (20).
Recombinantly expressed metabolic enzymes are useful
for determining the major enzymes responsible for the renal
metabolism of a drug. High variability in abundance, not only
between enzymes but also between batches for the same
enzyme, has been reported for recombinantly expressed
UGTs (e.g. 30.6% coefﬁcient of variation for rUGT1A4),
which may hinder IVIVE-based prediction of both hepatic
and renal glucuronidation clearance (14). In addition, UGTs
expressed in insect cells may have a substantial amount of
inactive protein present that can be reduced by lowering the
amount of baculovirus used to infect cells (21). Therefore, the
use of metabolic rate data from recombinant UGTs in a
quantitative IVIVE setting may require correction for
presence of inactive enzyme. Comparison of activity of probe
substrates across various in vitro systems and/or batches to
generate intersystem extrapolation factors (ISEF) should be
considered for prediction of renal glucuronidation clearance
from recombinant systems. These concepts are well
established and widely used for IVIVE of CYP-mediated
hepatic clearance from recombinant data (1). Emerging
quantitative proteomic data on renal metabolic enzymes (15,
22), improved understanding of regional differences in their
expression and differences in the enzyme expression in the
microsomal/cellular systems relative to the kidney are crucial
for the quantitative prediction of renal metabolic clearance;
these challenges are discussed in more detail in part II.
Measurement of Renal Passive Tubular Permeability In Vitro
Quantitative prediction of renal excretion clearance
requires consideration of each of the contributing processes,
i.e. glomerular ﬁltration, active secretion and tubular reab-
sorption. Passive renal tubular reabsorption of drugs has been
correlated with drug lipophilicity and other physico-chemical
properties (23, 24). Recently, a quantitative structure-
pharmacokinetic relationship (QSPKR) model has been
developed for prediction of reabsorption clearance, although
prior information on the dominant process (reabsorption or
secretion) and/or Biopharmaceutical Drug Disposition and
Classiﬁcation System (BDDCS) class is required (25).
Currently, there is no consensus on the recommended in
vitro system to assess renal passive tubular permeability in
vitro. Some studies have proposed the use of permeability
data following apical-basolateral transport across Lewis lung
carcinoma pig kidney (LLC-PK1) cells for the assessment of
tubular reabsorption in the human proximal tubule (26).
Methods for culturing primary renal tubule cells have been
published for the remaining sections of the nephron tubule
(loop of Henle through collecting duct), but these are not
routinely used for permeability and drug transport studies,
e.g. (27). In contrast, the collecting duct-derived Madin-
Darby canine kidney (MDCK) cell line is routinely used for
drug permeability and transport studies (following transfec-
tion with speciﬁc human drug transporters), typically in the
context of oral drug absorption and brain penetration (28).
Similarly, Caco-2 cells are widely used as an in vitro model of
intestinal, as well as blood–brain barrier permeability, and
have recently been proposed as a possible in vitro model of
passive renal tubular reabsorption (29). Caco-2 cells differ
from kidney proximal tubule cells with respect to presence of
mucosa, immune cells, apical receptors (megalin) and drug
transporters (e.g. urate transporter 1 (URAT1/SLC22A12)
and OAT4 (SLC22A11) are not present in Caco-2). Never-
theless, use of transporter inhibitors in the assay minimises
the impact of transporter differences. This approach allows
the data from a routine Caco-2 permeability assay to be
scaled by corresponding tubular surface area to predict
passive tubular reabsorption, as illustrated recently for 45
drugs (29). Such differences in physiological characteristics
between cell lines (LLC-PK1, Caco-2 and MDCK) and renal
tubule cells in different regions of the nephron need to be
considered during data analysis and subsequent modelling
exercises. In addition, performing permeability assay under
the apical to basolateral pH gradient (e.g. of pH 6.5 to 7.4) is
important to mimic typical conditions observed in the renal
proximal tubule. This is of particular relevance for basic drugs
where use of the apparent permeability (Papp) data obtained
under isotonic pH 7.4 conditions resulted in pronounced
under-prediction of CLR (29).
In Vitro Systems to Study Active Transport in Kidney
Active tubular secretion and reabsorption in kidney are
mediated by a number of drug transporters expressed in the
epithelium of the proximal tubule cells. Summary of key drug
transporters expressed in human and rodent kidney proximal
tubule cells is shown in Table II. Various in vitro models to
study active transport of drug in kidney have been reported,
although a ‘gold standard’ assay format is currently lacking,
as summarised in Table III. The selection of the most
appropriate in vitro system will depend on the question/
hypothesis being investigated and constraints such as cost or
availability of fresh human kidney tissue. There is some
overlap with in vitro models used to investigate drug transport
in the liver, as recently reviewed (31). Variability in trans-
porter kinetic parameters observed between different exper-
imental systems and laboratories and its implications will be
addressed in more detail in part II.
Transfected Cells
Cell lines such as MDCK-II, Chinese hamster ovary
(CHO), human embryonic kidney (HEK-293) and HeLa can
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be stably or transiently transfected to express renal drug
transporters (8, 32, 33). Transfected cell lines are widely used
and commercially available and allow measurement of kinetic
parameters for individual transporter(s) and drug combina-
tions, including investigation of inhibitory potency as either
IC50 or inhibition constants (Ki). Drug uptake and efﬂux can
be studied simultaneously using multiple transfection of
transporters in a single cell line (32, 34). Whilst tight control
of transporter expression is possible (i.e. low between
occasion variability), the relative expression, abundance
and/or activity of multiple transporters in transfected cells
may not necessarily represent the in vivo setting. Differences
in transporter expression levels can be accounted for as REF
scaling factors based on emerging proteomic abundance data
(22); however, examples of this approach are limited for
kidney and in some instances these scalars have been
estimated using clinical data, as reported for pemetrexed
(8). Furthermore, expression vs. activity relationships need to
be addressed both in vitro and in vivo before transporter-
speciﬁc REFs can be used with conﬁdence.
Primary Cultured Renal Tubule Cells
Primary renal tubule cells can be cultured in vitro for
several cell generations whilst maintaining multiple charac-
teristics of the cells of origin (13, 35). In addition, expression
and function of several major drug transporters and enzymes
are well maintained following a few days in culture, although
reduced expression may be expected after longer culture
times (13, 35, 36). Such in vitro models of proximal tubule
drug transport enable a holistic understanding of the pro-
cesses; for example, reduction in functional activity due to
inhibition or knockdown of one or more transporters can be
investigated. Inter-individual variability can also be studied,
Table II. Summary of Key Drug Transporters Expressed in Human and Rodent Kidney
Transporter Human? Rat/mouse? Comments
OCT2/Oct2 ✓ BL ✓ BL
OAT1/Oat1 ✓ BL ✓ BL
OAT2/Oat2 ✓ BL ✓✗ AP Relevance of OAT2 to transport in
human kidney debated
Immunohistochemistry indicates
Oat2 localised to loop of Henle in
rat
OAT3/Oat3 ✓ BL ✓✗ BL
OAT4 ✓ AP ✗ –
Oat5 ✗ – ✓ AP
OCTN1/Octn1 ✓✗ ? ✓ AP Both positive and negative ﬁndings
for expression in human kidney
OCTN2/Octn2 ✓ AP ✓ AP
Octn3 ✓ – ✓ AP
PEPT1/Pept1 ✓ ? ✓ AP
PEPT2/Pept2 ✓ AP ✓ AP
MATE1/Mate1 ✓ AP ✓ AP
MATE2-K ✓ AP ✗ – Human MATE2-K belongs to class
II subgroup of MATE transporters,
no rodent ortholog exists; rodent
Mate2, expressed predominantly in
testes, belongs to class III subgroup
and has been proposed to be
renamed Mate3 but this is not in
common use
MDR1/Mdr1a and Mdr1b ✓ AP ✓✗ ? Both positive and negative ﬁndings
for expression in rodent kidney
MRP2/Mrp2 ✓ AP ✓ AP
MRP4/Mrp4 ✓ AP ✓ ?
Oatp1a1 ✗ – ✓ AP
Oatp1a3 ✗ – ✓ AP
Oatp1a6 ✗ – ✓ AP
OATP4C1/Oatp4c1 ✓ ? ✓ ? Conﬂicting literature reports for rat
Oatp4c1 loca l i sa t ion ; apica l
localisation supported by functional
activity data; human OATP4C1
l o c a l i s a t i on t o ba so l a t e r a l
membrane hypothesised based on
functional activity data alone
Further details and references in the supplementary material, Tables S-I, S-II and S-III
✓ strong evidence of expression in kidney, ✗ transporter not present in particular species or not expressed in kidney, ✓✗ evidence for
expression in kidney is equivocal, AP apical membrane, BL basolateral membrane, – not relevant, ? not determined or conﬂicting data
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which should be distinguished from other factors such as
differences in tissue quality and experimental variability.
Extended research using primary cells depends on the
availability of a consistent supply of quality human tissue,
whilst obtaining reliable estimates of kinetic parameters,
especially for speciﬁc transporters, can be challenging. As
highlighted for renal metabolism, scaling of transporter
kinetic parameters generated in tubular cells is performed
using PTCPGK (Table III).
Kidney Slices
Kidney slices can be used to investigate drug uptake at
the basolateral membrane but not tubular reabsorption (37,
38). An advantage of kidney slices is that the interactions of
multiple substrates, inhibitors and endogenous transporters
can be investigated in this complex system (38). Imaging
technology (e.g. confocal microscopy, imaging mass spec-
trometry) can be used to support such studies and indicate the
localisation of uptake and inhibition of renal drug transporter
substrates, including those with therapeutic or toxicological
effects in kidney (39, 40). The uptake of drugs in kidney slices
can be affected by inter-batch and/or inter-individual vari-
ability (37), which must be considered for any IVIVE
strategy, e.g. by normalising data against the relative
activity/content of a marker in each kidney slice batch (38).
The IVIVE of transporter kinetic data generated in this
complex in vitro system is performed by kidney weight
(Table III). The main limitation to wider application of
human kidney slices is a consistent supply of quality tissue.
Other Cell Lines, Membrane Vesicles and ‘Kidney-on-a-Chip’
Several cell lines derived from kidney such as LLC-PK1,
Caki-1, HK-2, ci-PTEC, RPTEC/TERT1 and HKC have been
characterised, with some commercially available (e.g. http://
www.lgcstandards-atcc.org/), and can be generally useful for
investigating renal tubule function and toxicity in vitro (41–
44). For example ci-PTEC cells were used to investigate the
impact of CYP3A5 and P-glycoprotein (P-gp/MDR1,
ABCB1) genetic variation on tacrolimus metabolism, which
could allow mechanistic insights into nephrotoxicity
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during isolation, transfection (immortalised cells only) and/or cell culture
DDI drug–drug interaction, ISEF intersystem extrapolation factor, PTCPGK proximal tubule cells per gram kidney, REF relative expression
factor (ratio of in vivo to in vitro expression), RAF relative activity factor (ratio of in vivo to in vitro activity)
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associated with this calcineurin inhibitor (44). The same
system was used to demonstrate the inhibitory effect of
uremic toxins (commonly accumulated in chronic kidney
disease) on UGT activity which may have a signiﬁcant impact
on drug elimination in patients with renal impairment (45).
An important limitation for some of these cell lines is that
functional expression of drug transporters, particularly OAT1
(SLC22A6) and OAT3 (SLC22A8), or other renal character-
istics can be lost (46), although some of the recent advanced
molecular biology tools may be useful to overcome such
issues (47).
Cell membrane vesicles can be isolated from tissue
samples, cell lines and recombinantly expressed transporter
systems (48, 49), allowing multiple or individual transporters
to be studied. The inside-out vesicular transport assay is
particularly useful for studying transport mediated by efﬂux
transporters, which can be challenging when in standard cell-
based assays. It should be noted that inside-out vesicles can
be generated from overexpression systems but not usually
from native kidney tissue. The use of membrane vesicles is
limited to drugs with low lipophilicity/passive permeability.
Drugs with high lipophilicity/permeability will show high
levels of nonspeciﬁc binding to lipid bilayer of the vesicle
and may not be trapped within the vesicles following uptake,
making it difﬁcult to measure transporter-related uptake rates
(48).
Recent advances in molecular and cellular biology,
combined with micro-engineering, have led to a number of
proposed ‘next-generation’ in vitro models of the kidney and
other organs. These models may incorporate features such as
co-culture of multiple cell types (epithelium, endothelial and
pericytes), ﬂuid ﬂow (e.g. microﬂuidic devices such as ‘organ-
on-a-chip’) and 3D cell culture system, which have all been
suggested to provide more physiologically representative in
vitro systems for studying renal drug disposition (30, 50, 51).
Other emerging technologies, including stem cell science and
3D bio-printing, offer further potential for the development
of the next-generation in vitro models (52). The application of
these technologies to address questions on renal drug
disposition and the translational value of the data generated
remains a challenge for the future. A key question is whether
next-generation in vitro models offer sufﬁcient advantages
over traditional methods to justify the additional effort and
expertise required to generate suitable data.
Mechanistic Modelling of in Vitro Transporter Kinetic Data
Estimation of transporter kinetic parameters from in
vitro assay data is a key step for successful IVIVE of
transporter-mediated drug disposition, with recommendations
recently published by the International Transporter Consor-
tium (53). Important considerations pertinent also to IVIVE
of renal clearance mediated via drug transporters are
highlighted below.
Whilst uptake CLint data can be used in IVIVE
approaches, consideration of full kinetic proﬁle in vitro (i.e.
estimation of transporter Km and Vmax) is preferable, to
account for potential saturation issues (4, 53). Uptake
transporter kinetic parameters can be estimated from cell-
based in vitro uptake assays using the conventional two-step
method (8). The main disadvantages of the two-step method
are that data are generated using parallel experiments under
different conditions (e.g. 37°C vs. 4°C, transfected vs. mock
transfected cells, standard media vs. media containing speciﬁc
transporter inhibitor) and that bidirectional nature of passive
permeability is not considered. An alternative method is the
application of mechanistic compartmental modelling which
relies on simultaneous ﬁtting of uptake rates, bidirectional
passive diffusion, intracellular binding and cellular metabo-
lism (if relevant), as described for hepatocytes (54). The
biggest constraint with such mechanistic models is the
requirement for large amount of data (range of time points
and substrate concentrations) to support parameter estima-
tion. So far, complex mechanistic models have not yet been
applied in the experimental settings and data analysis
involving renal tubule cells.
Estimation of efﬂux transporter kinetic (Km,app, Jmax)
and inhibition (IC50,app) parameters is generally based on the
use of extracellular medium concentrations of either substrate
or inhibitors. Parameter estimates obtained this way are often
dependent on expression levels of efﬂux transporters (55, 56),
and this type of analysis is currently considered inadequate
(53). Compartmental modelling approaches are recom-
mended for estimation of mechanistic efﬂux transporter
kinetic parameters in monolayer assays (53, 55, 56). These
models differ in their complexity and may also consider
membrane partitioning and organelle (lysosomes) sequestra-
tion, ionised drug permeation, impact of the unstirred water
layer and the contribution of electrochemical gradients (53,
56–59). The key advantage of these models is consideration of
the interaction of an efﬂux transporter with the unbound
intracellular drug concentration, as opposed to nominal
incubation concentration. The application of such mechanistic
models is vital for generation of mechanistic in vitro
parameters describing kinetics of renal transporters to be
used subsequently in PBPK models. This is of particular
importance considering some of the complexities associated
with renal transporters. For example, under appropriate in
vitro conditions (e.g. expression system, pH gradient/
membrane potential), some renal drug transporters (including
multidrug and toxin extrusion protein 1 (MATE1, SLC47A1)
and 2-K (MATE2-K, SLC47A2) and OAT4 (SLC22A11)
expressed on the apical membrane of proximal tubule cells in
vivo can act as both uptake and efﬂux transporters (8, 32),
highlighting the importance of careful interpretation of such
in vitro data when translating to in vivo.
UNDERSTANDING THE PHYSIOLOGY OF KIDNEY:
THE KEY SYSTEM DATA IN PBPK MODELS
Mechanistic kidney models represent a simpliﬁcation of
kidney anatomy and physiology (Fig. I) but due to the
complexity of the organ may still incorporate a large number
of parameters. In silico models of kidney physiology are
typically implemented for rat (61, 62), for which detailed
physiological system data are generally more widely available
than for human, and are associated with a larger amount of in
vivo and in situ measurements on relevant input–output
relationships. This section will critically assess availability of
human renal physiology data important to inform system
parameters of mechanistic kidney PBPK models. In some
instances, data from preclinical species may be used to bridge
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the gap or uncertainty associated with the human physiolog-
ical data and this will be indicated in sections below. Certain
system parameters (e.g. protein expression) can be used in
conjunction with the corresponding measurements for the in
vitro system, to derive scaling factors (e.g. REF) for IVIVE of
in vitro metabolism or transporter data, as highlighted below.
Kidney Weight, Volume and Blood Flow
Kidney weight or volume and renal blood ﬂow are
implemented as parameters in whole-body PBPK models,
regardless of complexity of kidney model implemented, and
are relevant to both renal excretion and renal metabolism of
drugs. Kidney weight may also be used as an IVIVE scaling
factor for in vitro data generated in kidney slice assays
(Table III). Data on the weight and volume of human kidney,
including potential covariation with factors such as age,
gender, ethnicity, body weight and/or body height, have been
reported and collated previously (7, 63–65). Inter-study
variability may be low when using the same method to
measure kidney size, whereas there appears to be systematic
differences between the different methodological approaches
(66, 67). The decrease in kidney volume with age in adults
(approx. 23 mL per decade after 50 years old) appears to be
driven primarily by a decrease in cortical volume (approx.
18 mL per decade after 50 years old) (68). Data reported in
paediatric populations have been collated and discussed
elsewhere (69). Kidney weight and volume have been
reported to both increase and decrease in kidney disease,
depending on the stage and underlying cause of disease
(Table IV). In fact, kidney size and cortical volume have been
proposed as markers to aid diagnosis of kidney diseases (68,
70). Literature analysis of human kidney blood ﬂow (average
16.4 mL/min/kg, 20% of cardiac output) and associated inter-
individual variability has been reported previously (7). The
structural organisation of the intra-renal vasculature, intrinsic
to the physiological functions of the kidney, has been well
characterised (71, 72).
Tubular Flow Rates and pH Regulation
Glomerular ﬁltration rate is a fundamental physiological
parameter of mechanistic kidney models. This physiological
parameter is often associated with inter-individual variability,
Fig. I. Schematic view of a nephron and collecting duct depicting the structural characteristics
of epithelial cells forming various regions. Marieb, Elaine N.; Hoehn, Katja N., Human
Anatomy & Physiology, 10th, ©2016, p. 966. Reprinted by permission of Pearson Education,
Inc., New York, New York. (60)
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as well as bias in the methods commonly used to estimate it.
Wherever possible, mechanistic kidney models should be
informed by measured glomerular ﬁltration rate obtained
using inulin or iothalamate as markers. However, as tech-
niques for measuring glomerular ﬁltration rate are challeng-
ing and resource intensive, creatinine urinary clearance
(CLCR) is sometimes measured instead, despite evidence that
tubular secretion contributes to CLCR (3). More frequently,
CLCR and glomerular ﬁltration rate are estimated from serum
creatinine or cystatin C concentrations and demographic
information (e.g. Cockcroft-Gault or modiﬁcation of diet in
renal disease equations) (73). Although accurate within the
population group for which they are validated, these equa-
tions are typically imprecise and may not be accurate across
populations. Alternative equations have been developed for
infants and children (e.g. Schwartz equation, Counahan-
Barratt equation) (69). In addition, published data for
glomerular ﬁltration rate are usually normalised for body
surface area (i.e. per m2). This normalisation may not be
appropriate for obese subjects, as the absolute glomerular
ﬁltration rate (mL/min) has been found not to be
proportional to body surface area in these patients (74).
Furthermore, absolute glomerular ﬁltration rate should be
preferred for mechanistic kidney models, to be consistent
with the standard use of clearance parameters.
Glomerular ﬁltration rates in various population groups are
widely reported in the literature. A brief summary is given here;
for further information, interested readers should refer to the
following reviews (69, 73–75). Average values for healthy young
adult subjects are approximately 120–130 mL/min/1.73 m2.With
respect to age, glomerular ﬁltration rate (normalised to body
surface area) increases rapidly after birth from around 20–30%
of the adult value, reaching the adult level soon after 12 months
of age (69). After the age of 30 years, glomerular ﬁltration rate
declines with ageing, although some uncertainties exist around
the actual rate due to normal ageing, which has been reported at
a loss of 7.5–16.6 mL/min/1.73 m2 per decade (74, 76).
Glomerular ﬁltration rate decreases in patients with renal
impairment; in chronic kidney disease stages G1 (high and
optimal), G2 (mild), G3a (mild-moderate), G3b (moderate-
severe), G4 (severe) and G5 (kidney failure), glomerular
ﬁltration rates are >90, 60–90, 45–59, 30–44, 15–29 and
<15 mL/min/1.73 m2, respectively (73). Understanding of these
physiological changes and their implementation in the mecha-
nistic kidney models is key for the application of PBPK
modelling to predict pharmacokinetics in special populations
(e.g. obese or patients with renal impairment).
Table IV. Example Literature Reports of Differences or Changes in Kidney Size in Relation to Renal Function in Different Forms/Aetiologies
of Kidney Disease
Disease Reported changes in






Increase (volume) Rate of increase in kidney volume





Small decrease (length) No differences or decrease in renal
function and increase in kidney size
associated with presence/absence of








Decrease (length) Spiral CTA, sonography
Chronic glomerulonephritis Decrease (volume, length) Sonography
Diabetic nephropathy Increase in early stages,
decrease in later stages
(length, volume)
Prior to/during early kidney disease
progression, moderately increased
albuminuria is associated with glo-
merular hyperﬁltration and in-
creased renal volume in type 1
(insulin-dependent) diabetes and in





No changes found Sonography
CKD—aetiology
unspeciﬁed/mixed
Decrease (size) Some results not signiﬁcant Sonography
References are provided in supplementary material. No distinctions/inferences are made here regarding cause vs. effect relationships of renal
size and renal function in the different diseases, as pathophysiological mechanisms of kidney disease can form a cycle of disease progression
CTA computed tomography angiography, CRF chronic renal failure, EBCT electron beam-computerised tomography, MRI magnetic
resonance imaging
aRenal function assessed by various methods, including CLcr, eGFR and CLinulin
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Regional tubular ﬂow rates are an important consider-
ation in mechanistic models of passive tubular reabsorption.
Overview of estimates of renal tubular ﬂow rates in human
kidney has been reported recently (29). Approximately 70–
90% of ﬁltrate is reabsorbed in the proximal convoluted
tubule (29), whilst up to 15% of ﬁltered water can appear
in the urine during excessive water diuresis, when the distal
tubule and collecting duct regions of the nephron become
impermeable to water (77). Measurements of tubular
ﬁltrate reabsorption using the micro-puncture technique
can be used to infer regional tubular ﬂow rates; this
technique is not possible in humans, although one study
was found in rhesus monkey (78). Human tubular ﬂow
rates can also be inferred from differential changes in urine
composition/ﬂow rate in response to vasopressin levels
between healthy and hereditary nephrogenic diabetes
insipidus patients (77, 79). The micro-puncture technique
can be used to study regional differences in tubular ﬁltrate
pH; studies in rat indicate that the urine (pH 6.1) is more
acidic than the proximal tubule ﬁltrate (pH 6.7) in control
conditions, but each of these can vary under different
pathophysiological states such as acidosis (80).
Nephron Number
Nephron number can be an important system param-
eter in mechanistic kidney models as it allows scaling of
data from a single nephron to the level of the whole
kidney. For example, the tubular surface area of a single
‘average’ nephron can be used in conjunction with
nephron number to estimate the total tubular surface area
in the whole kidney. Nephron number has been exten-
sively studied through the measurement of glomerular
number (64, 65, 81). Whilst there are about 900,000
nephrons per human kidney on average, large inter-
individual variability exists in human nephron number
(ranging from 210,000 to 2.7 million (81)). Factors such as
age, kidney weight and birth weight are being suggested
as covariates, although such ﬁndings are generally incon-
sistent between studies (65, 81).
The collecting ducts form a branched tubular structure in
the inner medulla, and each cortical collecting duct accepts
the ﬁltrate from several distal tubules (82). Therefore, there is
a drastic reduction in the number of distinct tubules between
the beginning of the cortical collecting ducts (approx. 90,000
per kidney) and the ducts of Bellini (approx. 250 per kidney);
the implications of these on the estimation of the tubular
surface area and subsequently prediction of tubular reabsorp-
tion have been published recently (29).
Tubule Dimensions and Surface Area
Tubular surface area and its regional differences are
important consideration for mechanistic prediction of the
extent of tubular reabsorption. In the mechanistic kidney
models, tubular surface area is used as scaling factor for
IVIVE of apparent permeability data from in vitro
monolayer assays (Table III). Literature data on the
dimensions of the proximal tubule, loop of Henle, distal
tubule and collecting duct regions of the human nephron
were recently collated (29). Data were found to be sparse,
and reported values varied within and between studies. As
an example, reported values of the length and diameter of
the human proximal tubule ranged from 12 to 25.6 mm
and 30 to 79.7 μm, respectively. Some of the variability
may be attributed to age, as proximal tubule length
increases during childhood and early adulthood, and
declines after around 30–40 years old (63). In addition
to the length, diameter and number of nephrons, the
presence of plasma membrane structures such as micro-
villi, microplicae and basolateral infolding impact the
estimate of the effective surface area for a given region
of the nephron and subsequently prediction of the extent
of tubular reabsorption.
Proximal Tubule Cell Number
The proximal tubule cell number is a system parameter
in PBPK kidney models and is used as a scaling factor for
IVIVE of transporter/metabolism in vitro data from cell-
based assays (Table III), analogous to hepatocellularity. An
estimate of the proximal tubule cell number in human kidney
is currently not reported in the literature. Data exist in
preclinical species, where a single study reported a mean
number of rat proximal tubule cells of 92 million cells, with a
corresponding mean kidney weight of 0.99 g (83). Stereology,
which has been used for counting glomeruli number in
kidney, is proposed as a suitable method for measuring
absolute numbers of proximal tubule cells (83). In the
absence of directly measured values, proximal tubule cell
number can be inferred indirectly using relevant data from
disparate literature sources (see Supplementary material for
full details). Calculated values range from 30.2 to 209.2
million proximal tubule cells per gram kidney, in agreement
with a report that 70 million cells, primarily of proximal
tubule origin, can be isolated from 1 g of human renal cortical
tissue (84). These calculated values are based on numerous
assumptions and should therefore be treated as
approximations.
Microsomal and Cytosolic Protein Content of Kidney
The amounts of microsomal and cytosolic protein in
an organ are used as scaling factors for IVIVE of in vitro
metabolism data generated in the corresponding subcellu-
lar fractions. In kidney, these scaling factors are the
MPPGK and cytosolic protein per gram kidney (CPPGK).
Summary of the four studies reporting microsomal recov-
ery in kidney microsomes, i.e. MPPGK, is shown in
Table V. There is over ﬁve-fold difference between the
highest and lowest study averages, although data from the
two most recent studies are in closer agreement (15, 85).
It is interesting to note that the highest MPPGK value is
reported for cortex (88), and this may be attributable to
high amount of endoplasmic reticulum in cortex compared
to medulla (15). Due to the low number of subjects (total
of 23) and methodological differences (cortex vs. mixed
kidney or unspeciﬁed region), it is challenging to assess
the impact of potential covariates (e.g. age and gender)
on the kidney microsomal protein content, as previously
done for liver microsomal protein (89). No data currently
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exist for human CPPGK, and research is ongoing to
expand the available data for human MPPGK (90).
Amount of Specific Drug Metabolising Enzymes in Kidney
Drug-metabolising enzyme expression data can be used
as system parameters in PBPK models in order to account for
inter-individual variability in drug metabolism. Expression
and activity data suggest that UGT1A9 and UGT2B7 are the
major UGT enzymes in human kidney, with UGT1A9
expressed at levels close to or higher than those measured
in liver (91). These ﬁndings are in agreement with the
majority of quantitative abundance data from commercially
available pooled human kidney microsomes, acquired using
targeted LC-MS/MS proteomic methods (14, 92). Large
variability in both mRNA (72–85% CV, n = 11) and protein
abundance (76–159% CV, n = 10) has been noted for
UGT1A6, 1A9 and 2B7 in kidney homogenates prepared
from unspeciﬁed regions of healthy kidney (93). Lower
expression and abundances were observed in tumoral kidney
homogenates, although variability reported was comparable
to those in healthy kidney (93). In contrast to homogenates,
lower variability in UGT1A6, 1A9 and 2B7 abundance was
reported in microsomes from human kidney cortex (48–61%
CV, n = 5), mixed kidney (32–44% CV, n = 5) and kidney
medulla (15). The differences in the two studies could be due
to the low number of individual samples, which may not be
sufﬁcient to accurately determine inter-individual variability,
or contribution of technical variabilities which were not
assessed in either study. Absolute abundance data generated
using targeted LC-MS/MS can vary between studies and
laboratories (94); therefore, further work is required to assess
inter-laboratory variability to facilitate standardisation of
proteomic methods.
Amount of Specific Drug Transporters in Kidney
PBPK kidney models include system parameters to
account for transporter expression and associated inter-
individual variability in these data. IVIVE of transporter
kinetic data from cellular in vitro systems is performed by
REF scalars to account for differences in the expression
between in vivo and in vitro (Table III). Several studies
have measured the mRNA levels of the kidney drug
transporters, e.g. (3, 37, 46); the overall trends suggest
substantial inter-individual variabilities in the expression
of drug transporters, consistent with limited available
functional activity data (37). Quantitative proteomic trans-
porter abundance data are available for human organs
such as intestine, liver and brain (95–97), as well as rat
kidney (98). Data for human kidney have recently been
published; of the solute carrier transporters (SLC),
MATE1 and OAT3 were the most abundant (10.8 and
9.7 pmol/mg microsomal protein, respectively), whereas P-
gp/MDR1 was the most abundant ATP-binding cassette
(ABC) transporter (4.45 pmol/mg microsomal protein)
(22). Although data are available concerning renal devel-
opmental patterns of transporters in rodent species,
minimal expression data are available for human (99).
LC-MS/MS methods are currently favoured for measuring
transporter abundance in tissue homogenates and subcel-
lular fractions due to the high precision and ability to
assess inter-individual and inter-study variability in trans-
porter expression (96). Complimentary technologies such
as matrix-assisted laser desorption/ionisation (MALDI)-
imaging mass spectrometry, secondary ion mass
spectrometry and ﬂow cytometry (100, 101) may allow
quantitative analysis of transporter localisation at the
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a Predicted MPGGL for a 36-year-old is 39.4 mg protein/g liver, using model proposed by Barter et al. [89]
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tissue and/or subcellular scales (e.g. total protein vs.
functional protein) to be possible in the future. However,
secondary ion mass spectrometry-based methods require
further development before analysis of large proteins such
as drug transporters is possible (100).
PERSPECTIVE ON CURRENT EFFORTS
This review provides a critical analysis of different in
vitro tools currently available to investigate renal drug
metabolism and transport, in conjunction with key system
parameters necessary for mechanistic ‘bottom-up’ predic-
tion of renal drug disposition. Selection of suitable in
vitro assays and experimental design should be driven by
the scientiﬁc question(s) and properties of the compound
of interest. For example, transfected cell lines or recom-
binant enzyme expression systems may be more suitable
for investigating the interaction of drugs with individual
transporters or enzymes, whereas primary cultured prox-
imal tubule cells are more appropriate when a holistic
understanding of the interplay of different processes is
required (Table III). Potential limitations of each system,
as well as details of assay design (e.g. appropriate time
points, bio-analysis methodology), must be considered to
ensure that quality and ﬁt-for-purpose in vitro data are
acquired. The importance of optimisation of assay
conditions should not be underestimated. It is expected
that the wide range of in vitro systems currently available
to study renal drug disposition will be expanded by
ongoing research. Efforts to develop novel in vitro
platforms to investigate nephrotoxicity rely on molecular
biology and micro-engineering technologies to improve
physiological features of cells cultured in vitro to mimic
renal cells in vivo (47, 50, 51). Systems developed for the
purpose of toxicity screening that feature active expres-
sion of relevant drug-metabolising enzymes and trans-
porters may also be useful for studying renal drug
disposition in vitro, in order to generate data for
prediction of pharmacokinetic parameters.
System data represent an essential component of
PBPK models allowing quantitative extrapolation to other
populations/patients/scenarios. Ongoing work aimed at
measurement of protein abundances of renal drug-
metabolising enzymes and drug transporters remains a
high priority. Additional studies to assess the consistency
of proteomic methods and cross-laboratory comparisons of
abundance data using the same biological samples are
needed to differentiate between biological and technical
variability in expression levels. Once available, abundance
data from large cohorts of individuals could allow for co-
variates and protein–protein correlations to be established
whilst assessing the impact of particular demographic
features such as age and renal impairment. Sample
availability in particular patient groups will remain a
substantial limitation in the generation of these data. In
particular, paediatric PBPK models require information on
the ontogeny of the abundance and activity of drug-
metabolising enzymes and transporters; in contrast to
hepatic drug-metabolising enzymes, such data are lacking
for human kidney (99, 102). Using suitable techniques to
quantify differences in protein abundance in different
regions of the nephron, such as the convoluted vs. straight
portion of proximal tubule, would allow reﬁnement of the
current mechanistic models (5). Some system data can be
measured in both human and preclinical species (e.g.
blood ﬂow, microsomal protein recoveries, proximal tubule
cellularity and protein abundances) and for those param-
eters species differences can be established. For other
physiological features such as regional tubular ﬁltrate ﬂow
rates and pH, where direct access to the intact, functional
kidney is required for measurements, data from preclinical
species may be used as surrogate for systems parameters
in models of human kidney.
The uncertainties around parameters such as ﬁltrate
ﬂow rate and pH may eventually limit the level of
complexity that can be built into mechanistic models of
human kidney (or the level of certainty in absolute values
of systems parameters in complex models). This contrasts
with published models of rat kidney, for which the
available data support the mathematical description of
features such as exponential decline in proximal tubule
ﬁltrate ﬂow and compliant tubules (61). Despite uncer-
tainties associated with some human kidney systems
parameters, recent modelling efforts have attempted to
account for the impact of ﬂow rates and pH on tubular
drug reabsorption (29), as well as the effects electrochem-
ical gradients on organic cation transporter (OCT) 2
(OCT2, SLC22A2)-mediated secretion (59) in mechanistic
kidney models. The importance of accounting for the
impact of urine pH on proton gradient-dependent drug
transport by MATE1 and MATE2-K, as described in vitro
(103), should also be assessed.
CONCLUSION
Physiologically based prediction of renal clearance
depends on both high quality in vitro data and sufﬁcient
knowledge of human physiology in different population
groups. As highlighted, various kidney in vitro systems
are currently available but generally lack the level of
characterisation seen for hepatic in vitro systems and
corresponding models. More complex in vitro systems
such as those involving micro-ﬂuidics require sophisti-
cated in vitro modelling in order to obtain parameters of
translational relevance. Quantitative renal physiology
data important to inform mechanistic kidney model
parameters have been summarised here. It is evident
that given the complexity of these models and large
number of system parameters, a number of knowledge
gaps still exist, especially in our understanding of changes
in physiological parameters in special populations. These
can arise because of ethical constraints, difﬁculties in
obtaining human kidney tissue (particularly for paediat-
rics or renal impairment) or technological limitations.
Development of novel technologies, such as progresses in
quantitative proteomics, should allow generation of data
that are currently lacking to reﬁne further PBPK-IVIVE
of renal drug disposition.
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